CD366 (TIM3) Rat anti-Mouse, Clone: RMT3-23, eBioscience™

Rat Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 14-5870-85

500UG:ANTI-MOUSE TIM3 PURIFIED 500 UG

UNSPSC: 12352200

Code: Z2

Additional Details:
Additional Details: Weight: 0.01000kg



Disclaimers: For Research Use Only.

Product Code. 15297527

Quantity Price
1 £ 247.0 / 500µg
Estimated Shipment date
from Supplier 07-12-2016
Add to basket


Description and Specification

Specification

Antigen CD366 (TIM3)
Applications Flow Cytometry
Clone RMT3-23
Concentration 0.5mg/mL
Conjugate Unlabeled
Format Purified
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Gene Alias TIM-3, HAVCR2, T cell immunoglobulin domain, mucin-like domain
Host Species Rat
Isotype IgG2a
Quantity 500μg
Regulatory Status RUO
Species Reactivity Mouse
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal

The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4+Th1 and CD8+Tc1 cells, but is absent on CD4+Th2 and CD8+Tc2 cells. Other hematopoietic cell types, including naïve T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4+ and CD8+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4+ cells in the periphery expressed CD366 after immunization.

RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production.